{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:36Z","timestamp":1787800836759,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10620-026-09939-x","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:48:02Z","timestamp":1778071682000},"page":"4235-4241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recruitment of Minority Patients in Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials"],"prefix":"10.1007","volume":"71","author":[{"given":"Sarah E.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Wollstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"9939_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology."},{"key":"9939_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","volume":"16","author":"NE Rich","year":"2018","unstructured":"Rich NE, Oji S, Mufti AR et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the united states: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198-210.e2. https:\/\/doi.org\/10.1016\/j.cgh.2017.09.041.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9939_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al. A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med."},{"key":"9939_CR4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med."},{"key":"9939_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4254\/wjh.v12.i8.506","volume":"12","author":"P Patel","year":"2020","unstructured":"Patel P, Muller C, Paul S. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: a systematic review and meta-analysis. World J Hepatol. 2020;12:506\u2013518. https:\/\/doi.org\/10.4254\/wjh.v12.i8.506.","journal-title":"World J Hepatol."},{"key":"9939_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/joim.13035","volume":"287","author":"MH Le","year":"2020","unstructured":"Le MH, Yeo YH, Cheung R, Wong VWS, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011\u20132016. J Int Med. 2020;287:711\u2013722. https:\/\/doi.org\/10.1111\/joim.13035.","journal-title":"J Int Med."},{"key":"9939_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000324","volume":"7","author":"P Ochoa-Allemant","year":"2023","unstructured":"Ochoa-Allemant P, Marrero JA, Serper M. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. Hepatol Commun. 2023;7:e0324. https:\/\/doi.org\/10.1097\/HC9.0000000000000324.","journal-title":"Hepatol Commun."},{"key":"9939_CR8","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000753","volume":"15","author":"H Burton-Murray","year":"2024","unstructured":"Burton-Murray H, V\u00e9lez C, Boyd T et al. Low prevalence of reporting of participant race and ethnicity in gastroenterology research publications. Clin Transl Gastroenterol. 2024;15:e1. https:\/\/doi.org\/10.14309\/ctg.0000000000000753.","journal-title":"Clin Transl Gastroenterol."},{"key":"9939_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u2013982. https:\/\/doi.org\/10.1056\/NEJMoa020047.","journal-title":"N Engl J Med."},{"key":"9939_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","volume":"131","author":"HS Conjeevaram","year":"2006","unstructured":"Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470\u2013477. https:\/\/doi.org\/10.1053\/j.gastro.2006.06.008.","journal-title":"Gastroenterology."},{"key":"9939_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/hep.20212","volume":"39","author":"LJ Jeffers","year":"2004","unstructured":"Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702\u20131708. https:\/\/doi.org\/10.1002\/hep.20212.","journal-title":"Hepatology."},{"key":"9939_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","volume":"5","author":"JM Loree","year":"2019","unstructured":"Loree JM, Anand S, Dasari A et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncology. 2019;5:e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","journal-title":"JAMA Oncology."},{"key":"9939_CR13","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.16680","volume":"326","author":"M Lolic","year":"2021","unstructured":"Lolic M, Araojo R, Okeke M, Woodcock J. Racial and ethnic representation in US clinical trials of new drugs and biologics, 2015\u20132019. JAMA. 2021;326:2201\u20132203. https:\/\/doi.org\/10.1001\/jama.2021.16680.","journal-title":"JAMA."},{"key":"9939_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100252","volume":"11","author":"BE Turner","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race\/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252. https:\/\/doi.org\/10.1016\/j.lana.2022.100252.","journal-title":"Lancet Reg Health Am."},{"key":"9939_CR15","unstructured":"Commissioner O of the. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies"},{"key":"9939_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","volume":"79","author":"AM Allen","year":"2023","unstructured":"Allen AM, Lazarus JV, Younossi ZM. Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties. J Hepatol 2023;79:209\u2013217. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.026.","journal-title":"J Hepatol"},{"key":"9939_CR17","unstructured":"Passel GM and JS. (2026) Facts About the U.S. Black Population. Pew Research Center. https:\/\/www.pewresearch.org\/race-and-ethnicity\/fact-sheet\/facts-about-the-us-black-population\/"},{"key":"9939_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.14309\/ajg.0000000000002756","volume":"119","author":"N Samala","year":"2024","unstructured":"Samala N, Xin Y, Wilson LA et al. Non-hispanic black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype. Am J Gastroenterol. 2024;119:1857\u20131865. https:\/\/doi.org\/10.14309\/ajg.0000000000002756.","journal-title":"Am J Gastroenterol."},{"key":"9939_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36307","volume":"6","author":"NI Zakaria","year":"2023","unstructured":"Zakaria NI, Tehranifar P, Laferr\u00e8re B, Albrecht SS. Racial and ethnic disparities in glycemic control among insured US adults. JAMA Netw Open. 2023;6:e2336307. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36307.","journal-title":"JAMA Netw Open."},{"key":"9939_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","volume":"44","author":"LT Clark","year":"2019","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL et al. increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44:148\u2013172. https:\/\/doi.org\/10.1016\/j.cpcardiol.2018.11.002.","journal-title":"Curr Probl Cardiol."},{"key":"9939_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jamapsychiatry.2025.0666","volume":"82","author":"A Bellato","year":"2025","unstructured":"Bellato A, Radu\u00e0 J, Stocker A et al. Reporting and representation of race and ethnicity in clinical trials of pharmacotherapy for mental disorders: a meta-analysis. JAMA Psychiatry. 2025;82:663. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0666.","journal-title":"JAMA Psychiatry."},{"key":"9939_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70457","author":"E Behling","year":"2025","unstructured":"Behling E, Farhat LC, Landeros-Weisenberger A, Bloch MH. Racial ethnic and sex representation in Tourette\u2019s Syndrome clinical trials: a meta-analysis. Mov Disord Clin Pract. 2025. https:\/\/doi.org\/10.1002\/mdc3.70457.","journal-title":"Mov Disord Clin Pract."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09939-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:14:50Z","timestamp":1787800490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09939-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9939"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09939-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}